Literature DB >> 20128995

Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers.

Zhaofei Liu1, Shuanglong Liu, Gang Niu, Fan Wang, Shuang Liu, Xiaoyuan Chen.   

Abstract

Integrin alphavbeta3 plays great roles in tumor angiogenesis, invasion, and metastasis. We report here the noninvasive visualization of tumor integrin alphavbeta3 expression by using near-infrared fluorescence (NIRF) imaging of an IRDye800-labeled new cyclic RGD (arginine-glycine-aspartic acid) dimer with tetra(ethylene glycol) (PEG4) linkers (ie, E[PEG4-c(RGDfK)]2, PEG4 = 15-amino-4,7,10,13-tetraoxapentadecanoic acid) in a U87MG tumor model. Fluorescent dye-labeled E[PEG4-c(RGDfK)]2 were subjected to in vitro cell staining, in vivo NIRF imaging, ex vivo NIRF imaging, and histologic studies. The in vitro and in vivo characterization of dye-labeled E[PEG4-c(RGDfK)]2 were compared with dye-labeled RGD dimer without PEG4 linkers (namely, E[c(RGDfK)]2). Both Cy5.5-E[PEG4-c(RGDfK)]2 and Cy5.5-E[c(RGDfK)]2 exhibited integrin alphavbeta3 binding specificity in a cell-staining experiment. In vivo NIRF imaging showed higher tumor accumulation and tumor to background contrast of IRDye800-E[PEG4-c(RGDfK)]2 over IRDye800-E[c(RGDfK)]2. The tumor integrin alphavbeta3 specificity of IRDye800-E[PEG4-c(RGDfK)]2 was confirmed by successful inhibition of tumor uptake in the presence of an excess dose of c(RGDfK). Histologic examination revealed both tumor vasculature and tumor cell integrin alphavbeta3 binding of IRDye800-E[PEG4-c(RGDfK)]2 in vivo. In summary, NIRF imaging with IRDye800-E[PEG4-c(RGDfK)]2 offers an easy, fast, and low-cost way to detect and semiquantify tumor integrin alphavbeta3 expression in living subjects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128995      PMCID: PMC3629979     

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  36 in total

Review 1.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

Authors:  B P Eliceiri; D A Cheresh
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 2.  Effect of pegylation on pharmaceuticals.

Authors:  J Milton Harris; Robert B Chess
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

3.  Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.

Authors:  Xianzhong Zhang; Zhengming Xiong; Yun Wu; Weibo Cai; Jeffery R Tseng; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

4.  Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles.

Authors:  Anne H Schmieder; Patrick M Winter; Shelton D Caruthers; Thomas D Harris; Todd A Williams; John S Allen; Elizabeth K Lacy; Huiying Zhang; Michael J Scott; Grace Hu; J David Robertson; Samuel A Wickline; Gregory M Lanza
Journal:  Magn Reson Med       Date:  2005-03       Impact factor: 4.668

Review 5.  Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.

Authors:  Weibo Cai; Xiaoyuan Chen
Journal:  Anticancer Agents Med Chem       Date:  2006-09       Impact factor: 2.505

6.  In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography.

Authors:  Angelika von Wallbrunn; Carsten Höltke; Michael Zühlsdorf; Walter Heindel; Michael Schäfers; Christoph Bremer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-28       Impact factor: 9.236

7.  Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner.

Authors:  Chunfu Zhang; Manfred Jugold; Eva C Woenne; Twan Lammers; Bernd Morgenstern; Margareta M Mueller; Hanswalter Zentgraf; Michael Bock; Michael Eisenhut; Wolfhard Semmler; Fabian Kiessling
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

8.  (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.

Authors:  Zi-Bo Li; Weibo Cai; Qizhen Cao; Kai Chen; Zhanhong Wu; Lina He; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

Review 9.  Multimodality imaging of tumor integrin alphavbeta3 expression.

Authors:  Xiaoyuan Chen
Journal:  Mini Rev Med Chem       Date:  2006-02       Impact factor: 3.862

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  16 in total

1.  Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor.

Authors:  Xianlei Sun; Teng Ma; Hao Liu; Xinhe Yu; Yue Wu; Jiyun Shi; Bing Jia; Huiyun Zhao; Fan Wang; Zhaofei Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

2.  Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.

Authors:  Ali Azhdarinia; Nathaniel Wilganowski; Holly Robinson; Pradip Ghosh; Sunkuk Kwon; Zawaunyka W Lazard; Alan R Davis; Elizabeth Olmsted-Davis; Eva M Sevick-Muraca
Journal:  Bioorg Med Chem       Date:  2011-05-06       Impact factor: 3.641

3.  Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.

Authors:  Yunpeng Ye; Baogang Xu; Gregory V Nikiforovich; Sharon Bloch; Samuel Achilefu
Journal:  Bioorg Med Chem Lett       Date:  2011-02-23       Impact factor: 2.823

4.  Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.

Authors:  Zhaofei Liu; Yan Liu; Bing Jia; Huiyun Zhao; Xiaona Jin; Fang Li; Xiaoyuan Chen; Fan Wang
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

5.  High-affinity peptide against MT1-MMP for in vivo tumor imaging.

Authors:  Lei Zhu; Huiling Wang; Lin Wang; Ye Wang; Kun Jiang; Cheng Li; Qingjie Ma; Shi Gao; Liping Wang; Wei Li; Mingjun Cai; Hongda Wang; Gang Niu; Seulki Lee; Wei Yang; Xuexun Fang; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-02-02       Impact factor: 9.776

Review 6.  Preclinical molecular imaging of tumor angiogenesis.

Authors:  L Zhu; G Niu; X Fang; X Chen
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 2.346

7.  Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma.

Authors:  Ruimin Huang; Jelena Vider; Joy L Kovar; D Michael Olive; Ingo K Mellinghoff; Philipp Mayer-Kuckuk; Moritz F Kircher; Ronald G Blasberg
Journal:  Clin Cancer Res       Date:  2012-08-22       Impact factor: 12.531

8.  Small molecule fluorophore and copolymer RGD peptide conjugates for ex vivo two-photon fluorescence tumor vasculature imaging.

Authors:  Alma R Morales; Ciceron O Yanez; Yuanwei Zhang; Xuhua Wang; Sanchita Biswas; Takeo Urakami; Masanobu Komatsu; Kevin D Belfield
Journal:  Biomaterials       Date:  2012-08-30       Impact factor: 12.479

9.  Integrin targeted delivery of radiotherapeutics.

Authors:  Zhaofei Liu; Fan Wang; Xiaoyuan Chen
Journal:  Theranostics       Date:  2011-03-01       Impact factor: 11.556

10.  Non-invasive imaging of endothelial progenitor cells in tumor neovascularization using a novel dual-modality paramagnetic/near-infrared fluorescence probe.

Authors:  Xin-Yi Wang; Shenghong Ju; Cong Li; Xin-Gui Peng; Alex F Chen; Hui Mao; Gao-Jun Teng
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.